Alto Neuroscience (NYSE:ANRO) Reaches New 52-Week High on Analyst Upgrade

Alto Neuroscience, Inc. (NYSE:ANRO)’s stock price hit a new 52-week high during mid-day trading on Tuesday after HC Wainwright raised their price target on the stock from $50.00 to $55.00. HC Wainwright currently has a buy rating on the stock. Alto Neuroscience traded as high as $34.35 and last traded at $33.70, with a volume of 863655 shares changing hands. The stock had previously closed at $32.14.

A number of other equities analysts have also weighed in on the company. Wolfe Research initiated coverage on Alto Neuroscience in a research report on Friday, May 22nd. They issued an “outperform” rating for the company. Wall Street Zen raised shares of Alto Neuroscience from a “strong sell” rating to a “sell” rating in a report on Saturday, August 15th. Bank of America began coverage on shares of Alto Neuroscience in a research note on Tuesday, May 5th. They issued a “buy” rating and a $35.00 price target for the company. Zacks Research lowered shares of Alto Neuroscience from a “hold” rating to a “strong sell” rating in a research note on Wednesday, July 22nd. Finally, BTIG Research boosted their price objective on shares of Alto Neuroscience from $28.00 to $37.00 and gave the company a “buy” rating in a report on Thursday, August 13th. Eight equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and two have issued a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $37.25.

Trending Headlines about Alto Neuroscience

Here are the key news stories impacting Alto Neuroscience this week:

• Positive Sentiment: HC Wainwright raised its FY2026 EPS forecast to a loss of $2.80 from $2.98 and lifted its FY2027 estimate to a loss of $3.87 from $4.39. Quarterly estimates were also improved, including Q3 2026 to a loss of $0.67 from $0.72 and Q4 2026 to a loss of $0.68 from $0.71. Alto Neuroscience Stock Price Expected to Rise, HC Wainwright Analyst Says
• Positive Sentiment: The analyst also reduced projected losses for 2027 through 2030, including FY2028 to a loss of $4.39 from $4.81, FY2029 to a loss of $3.25 from $3.50, and FY2030 to a loss of $1.29 from $1.53. These changes point to expectations for better long-term financial performance.
• Positive Sentiment: HC Wainwright maintained its $55 price objective, which remains above Alto Neuroscience’s recent trading level. The stock has climbed substantially over the past year and is trading close to its 52-week high, indicating strong investor momentum.
• Neutral Sentiment: Despite the improved forecasts, Alto Neuroscience is still expected to report losses in every period listed. The company’s current-year consensus estimate remains a loss of $2.71 per share, so the investment case continues to depend heavily on clinical and commercial progress.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of ANRO. Commodore Capital LP purchased a new position in shares of Alto Neuroscience in the fourth quarter worth approximately $32,453,000. Perceptive Advisors LLC increased its holdings in Alto Neuroscience by 1,048.5% during the fourth quarter. Perceptive Advisors LLC now owns 1,784,393 shares of the company’s stock valued at $31,762,000 after buying an additional 1,629,027 shares during the last quarter. Vestal Point Capital LP raised its position in Alto Neuroscience by 161.6% in the fourth quarter. Vestal Point Capital LP now owns 2,485,000 shares of the company’s stock worth $44,233,000 after acquiring an additional 1,535,000 shares during the period. Spruce Street Capital LP raised its position in Alto Neuroscience by 494.7% in the first quarter. Spruce Street Capital LP now owns 1,325,210 shares of the company’s stock worth $29,116,000 after acquiring an additional 1,102,366 shares during the period. Finally, Vivo Capital LLC bought a new position in Alto Neuroscience in the fourth quarter worth approximately $18,433,000.

Alto Neuroscience Stock Up 2.4%

The company’s 50 day moving average price is $26.85 and its two-hundred day moving average price is $23.18. The company has a current ratio of 14.85, a quick ratio of 14.85 and a debt-to-equity ratio of 0.07. The firm has a market cap of $1.37 billion, a PE ratio of -14.44 and a beta of 1.06.

Alto Neuroscience (NYSE:ANRO) last posted its quarterly earnings data on Wednesday, August 12th. The company reported ($0.65) EPS for the quarter, topping the consensus estimate of ($0.73) by $0.08. On average, equities research analysts expect that Alto Neuroscience, Inc. will post -2.68 EPS for the current fiscal year.

Alto Neuroscience Company Profile

Alto Neuroscience (NYSE:ANRO) is a clinical-stage biotechnology company dedicated to advancing precision medicine in neuropsychiatric disorders. The company leverages an integrated digital clinical neuroscience platform that gathers and analyzes multimodal biomarker data—such as electroencephalography (EEG), cognitive assessments and patient-reported outcomes—to predict individual treatment responses. This approach aims to accelerate drug development and improve therapeutic outcomes for conditions like major depressive disorder and treatment-resistant depression.

Alto’s proprietary platform combines data science, machine learning and proprietary algorithms to stratify patient populations and identify responders to investigational therapies.